LENZ NASDAQ
LENZ Therapeutics, Inc.
1W: +13.9%
1M: +1.0%
3M: -39.8%
YTD: -63.2%
1Y: -81.4%
$5.88
+0.18 (+3.16%)
Weekly Expected Move ±10.5%
$4
$5
$5
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$184.4M
52W Range4.68-50.4
Volume639,332
Avg Volume915,024
Beta1.62
Dividend$14.42
Analyst Ratings
Company Info
CEOEvert Schimmelpennink
Employees152
SectorHealthcare
IndustryBiotechnology
IPO Date2021-06-25
Websitelenz-tx.com
201 Lomas Santa Fe Drive
Solana Beach, CA 92014
US
Solana Beach, CA 92014
US
(858) 925-7000
About LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Latest News
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
Everest Medicines acquires Greater China rights for LENZ Therapeutics' presbyopia eyedrop VIZZ®
Lenz outlines sales force reaching 15,000 eye care professionals by quarter end as VIZZ adoption actions roll out
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RA CAPITAL MANAGEMEN | A-Award | 22,100 | $6.63 | 2026-06-15 |
| George Jeffrey P. | A-Award | 22,100 | $6.63 | 2026-06-15 |
| Drapkin Kimberlee C | A-Award | 22,100 | $6.63 | 2026-06-15 |
| MCCOLLUM JAMES W | A-Award | 22,100 | $6.63 | 2026-06-15 |
| Thunen Shelley B | A-Award | 22,100 | $6.63 | 2026-06-15 |